Drug intelligence / Profile preview

VCC-668662:01

Development stage: Unknown
Lead developer: Vichem Chemie Research
Modality: Small Molecules

Overview

VCC-668662:01 is a preclinical small molecule kinase inhibitor developed by Vichem Chemie Research. It acts as an ATP-competitive inhibitor within the PI3K-AKT-mTOR pathway, specifically targeting the mechanistic target of rapamycin (mTOR) with a reported IC50 of 51 nM. The compound is designed to modulate key components of the PI3K-AKT-mTOR signaling cascade, which is frequently dysregulated in various cancers and inflammatory conditions. Currently, VCC-668662:01 is in the early discovery and hit-to-lead stage of development.

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)RPS6KB1 (Ribosomal protein S6 kinase beta-1)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2

Beyond the preview

Go deeper on VCC-668662:01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCC-668662:01.